

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
27 October 2022 (27.10.2022)



(10) International Publication Number
WO 2022/226217 A1

(51) International Patent Classification:

A61K 47/18 (2017.01) C07C 23/100 (2006.01)

C12N 15/113 (2010.01)

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2022/025807

(22) International Filing Date:

21 April 2022 (21.04.2022)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/178,361 22 April 2021 (22.04.2021) US

63/261,506 22 September 2021 (22.09.2021) US

63/288,379 10 December 2021 (10.12.2021) US

(71) Applicant: **CIVI BIOPHARMA, INC.** [US/US]; 5425
Wisconsin Avenue, Chevy Chase, Maryland 20815 (US).

(72) Inventors: **OERUM, Henrik**; c/o CiVi Biopharma, Inc.,
5425 Wisconsin Avenue, Chevy Chase, Maryland 20815
(US). **NOBLE, Stewart Alwy**; c/o CiVi Biopharma, Inc.,
5425 Wisconsin Avenue, Chevy Chase, Maryland 20815
(US). **SHEAR, Charles Lester**; c/o CiVi Biopharma, Inc.,
5425 Wisconsin Avenue, Chevy Chase, Maryland 20815
(US).

(74) Agent: **COVERT, John M.** et al.; Sterne, Kessler, Gold-
stein & Fox P.L.L.C., 1100 New York Avenue, NW, Wash-
ington, District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: ORAL DELIVERY OF OLIGONUCLEOTIDES

(57) Abstract: The present disclosure provides oligonucleotide compositions comprising (i) an oligonucleotide of the present disclosure, e.g., an ASO, siRNA, shRNA, DNA or RNA aptamer, gene therapy vector, miRNA, miRNA mimic, antimiR, DNA or RNA decoy, CpG oligonucleotide, or any therapeutic or diagnostic oligonucleotide known in the art, and (ii) a caprylic acid derivative, e.g., 5-CNAC. In some aspects, the oligonucleotide composition is formulated for delivery to the gastrointestinal tract. Thus, some aspects, the present disclosure provides oligonucleotide compositions for oral delivery comprising a therapeutic or diagnostic oligonucleotide (e.g., an ASO) and a caprylic acid derivative (e.g., 5-CNAC or de derivative thereof).

WO 2022/226217 A1